Skip to content

About Us
Our Science
Media
Pipeline
- Overview
- AWARE-1
- BRACELET-1
- GOBLET
Investors
- Overview
- News
- Events
- Stock Information
- Filings
- Corporate Governance
- FAQs
Careers
Contact

About Us
Our Science
Media
Pipeline
- Overview
- AWARE-1
- BRACELET-1
- GOBLET
Investors
- Overview
- News
- Events
- Stock Information
- Filings
- Corporate Governance
- FAQs
Careers
Contact

About Us
Our Science
Media
Pipeline
- Overview
- AWARE-1
- BRACELET-1
- GOBLET
Investors
- Overview
- News
- Events
- Stock Information
- Filings
- Corporate Governance
- FAQs
Careers
Contact

About Us
Our Science
Media
Pipeline
- Overview
- AWARE-1
- BRACELET-1
- GOBLET
Investors
- Overview
- News
- Events
- Stock Information
- Filings
- Corporate Governance
- FAQs
Careers
Contact

News

Select Year
Clinical Trials
Search …

April 4, 2018

Oncolytics Biotech(R) to Present at the MicroCap Conference

March 20, 2018

Oncolytics Biotech(R) Scientist Selected to Participate in the Society of Immunotherapy of Cancer’s (SITC) METIOR Incubator Program

March 14, 2018

Oncolytics Biotech(R) Announces Publication of REOLYSIN(R) Abstract for the AACR 2018 Annual Meeting

March 9, 2018

Oncolytics Biotech(R) Inc. Announces 2017 Year-End Results

March 8, 2018

Oncolytics Biotech(R) Chief Medical Officer to Facilitate Roundtable Discussion at the US Immuno-Oncology Strategy Meeting

February 27, 2018

Oncolytics Biotech(R) to Present REOLYSIN(R) at the 2018 Precision: Breast Cancer World R&D Summit

February 23, 2018

Oncolytics Biotech(R) Announces Results from Special Meeting of Shareholders

February 14, 2018

Oncolytics Biotech(R) to Present at the RBC Capital Markets 2018 Healthcare Conference

February 1, 2018

Oncolytics Biotech(R) to Host Conference Call Outlining the Treatment Paradigm of Metastatic Breast Cancer Subtypes and Provide Topline Information on its Phase 3 Registration Study with REOLYSIN(R)

January 29, 2018

Oncolytics Biotech® Inc. Announces Plans to Apply to List Common Shares on the NASDAQ Capital Market

Page 29 of 69

Investor Relations Contact

Jon Patton
Director of Investor Relations & Communication
Email: jpatton@oncolytics.ca

Email Alerts Sign-Up

Email

I accept the Privacy Policy

Loading...

4350 Executive Drive
Suite 325
San Diego, CA 92121
info@oncolyticsbiotech.com

Company

About Us
Leadership
Scientific Advisors
Careers
Contact

Science

Our Science
Pipeline
Publications

Investors

Overview
News
Events
Stock Information
Filings
Corporate Governance
FAQs

Privacy Policy Accessibility Cookie Policy Disclaimer Sitemap Manage Consent

Copyright © 2025 Oncolytics Biotech Inc.